Yeahbutt.....R-IT patients stayed on their statins, so you can't extrapolate that data to non-statin compliant patients, which means RWE is really the only way to see if V works as standalone therapy - and that wouldn't be definitive, just suggestive. I really don't believe BP would spend the money to run a V only CVOT, too much money, would take too long, so they wouldn't have enough time left between results and gaining FDA approval to get a ROI before Teva enters the market. What I'd like to know is if the synergies of EPA + statin are due to anti-inflammatory effects of both drugs, and LDL-C is just a sideshow - meaning would someone with normal LDL-C who ordinarily wouldn't be prescribed a statin get a bigger CVD benefit from taking both drugs vs. just taking V - that would be an interesting trial, but again I don't see anyone ever finding a reason to run it.